10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This study examines whether the addition of decitabine to the standard Flu/TBI conditioning
regimen prior to allogeneic stem cell transplantation in poor and very poor risk AML
patients, reduces the risk of recurrence of the disease. Because decitabine has hardly any
side effects, it will likely have little impact on the occurrence of Graft Versus Host
Disease. The investigators are looking for a pre-treatment for transplantation which reduces
the chance of recurrence of the disease without involving severe damage to normal tissues.